<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02936505</url>
  </required_header>
  <id_info>
    <org_study_id>Version 3.0</org_study_id>
    <secondary_id>154-16</secondary_id>
    <secondary_id>2015-004137-27</secondary_id>
    <nct_id>NCT02936505</nct_id>
  </id_info>
  <brief_title>Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.</brief_title>
  <acronym>ScanCLAD</acronym>
  <official_title>A Scandinavian Controlled, Randomized, Open-label, and Multi-centre Study Evaluating if Once-daily Tacrolimus or Twice-daily Cyclosporin, Reduces the 3-year Incidence of Chronic Lung Allograft Dysfunction After Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen University Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A controlled randomized, open-label, multi-centre study evaluating if an immunosuppressive
      protocol, based on ATG-induction, once daily tacrolimus-dose (Advagraf®), mycophenolate
      mofetil and corticosteroid reduces the incidence of chronic lung allograft dysfunction (CLAD)
      after lung transplantation, in comparison with a standard cyclosporin-based protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study purpose:

      To evaluate whether the use of a once-daily tacrolimus-dose regimen (Advagraf®), based on
      anti-thymocyte globulin (Thymoglobulin®) induction, mycophenolate mofetil (MMF) and
      corticosteroids, reduces the cumulative incidence of CLAD after de novo lung transplantation
      at 36 months, in comparison with a twice-daily cyclosporin-based protocol, otherwise
      identical between groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with incidence of CLAD</measure>
    <time_frame>36 months</time_frame>
    <description>The cumulative incidence of CLAD (including both BOS and RAS, as defined by the ISHLT-criteria, Appendix II) at 36 months after lung transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate</measure>
    <time_frame>3 months</time_frame>
    <description>Renal function evaluated by measured glomerular filtration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary graft dysfunction</measure>
    <time_frame>72 hours</time_frame>
    <description>Cumulative incidence of primary graft dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite measure of freedom from AR, CLAD, graft and patient survival</measure>
    <time_frame>12 months</time_frame>
    <description>Composite measure of freedom from AR, CLAD, graft survival, and patient survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite measure of freedom from AR, CLAD, graft and patient survival</measure>
    <time_frame>24 months</time_frame>
    <description>Composite measure of freedom from AR, CLAD, graft survival, and patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite measure of freedom from AR, CLAD, graft and patient survival</measure>
    <time_frame>36 months</time_frame>
    <description>Composite measure of freedom from AR, CLAD, graft survival, and patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of primary graft dysfunction</measure>
    <time_frame>72 hours</time_frame>
    <description>cumulative incidence of primary graft dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>1 year</time_frame>
    <description>Patient survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>3 year</time_frame>
    <description>Patient survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of acute allograft rejection and CLAD</measure>
    <time_frame>6 months</time_frame>
    <description>The cumulative incidence of acute allograft rejection (AR) and CLAD. - Determined by clinical criteria, computed tomography (CT) and trans bronchial lung biopsy with broncho-alveolar lavage (BAL). - Number of rejections (cellular and antibody mediated), stratified by biopsy and non-biopsy verified rejections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of acute allograft rejection and CLAD</measure>
    <time_frame>1 year</time_frame>
    <description>The cumulative incidence of acute allograft rejection (AR) and CLAD. - Determined by clinical criteria, computed tomography (CT) and trans bronchial lung biopsy with broncho-alveolar lavage (BAL). - Number of rejections (cellular and antibody mediated), stratified by biopsy and non-biopsy verified rejections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of acute allograft rejection and CLAD</measure>
    <time_frame>3 year</time_frame>
    <description>The cumulative incidence of acute allograft rejection (AR) and CLAD. - Determined by clinical criteria, computed tomography (CT) and trans bronchial lung biopsy with broncho-alveolar lavage (BAL). - Number of rejections (cellular and antibody mediated), stratified by biopsy and non-biopsy verified rejections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of BOS and RAS</measure>
    <time_frame>6 months</time_frame>
    <description>The cumulative incidence of BOS and RAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of BOS and RAS</measure>
    <time_frame>1 year</time_frame>
    <description>The cumulative incidence of BOS and RAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of BOS and RAS</measure>
    <time_frame>3 year</time_frame>
    <description>The cumulative incidence of BOS and RAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of donor specific antibodies</measure>
    <time_frame>12 months</time_frame>
    <description>Development of donor specific antibodies (DSA) according to specific protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of donor specific antibodies</measure>
    <time_frame>24 months</time_frame>
    <description>Development of donor specific antibodies (DSA) according to specific protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of donor specific antibodies</measure>
    <time_frame>36 months</time_frame>
    <description>Development of donor specific antibodies (DSA) according to specific protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function mGFR</measure>
    <time_frame>12 months</time_frame>
    <description>Renal function evaluated by measured glomerular filtration rate (mGFR), by Iohexol or Cr-EDTA clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function mGFR</measure>
    <time_frame>24 months</time_frame>
    <description>Renal function evaluated by measured glomerular filtration rate (mGFR), by Iohexol or Cr-EDTA clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function mGFR</measure>
    <time_frame>36 months</time_frame>
    <description>Renal function evaluated by measured glomerular filtration rate (mGFR), by Iohexol or Cr-EDTA clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function cGFR</measure>
    <time_frame>3 months</time_frame>
    <description>Renal function evaluated by calculated glomerular filtration rate (cGFR), by three different Formulas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function cGFR</measure>
    <time_frame>12 months</time_frame>
    <description>Renal function evaluated by calculated glomerular filtration rate (cGFR), by three different Formulas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function cGFR</measure>
    <time_frame>24 months</time_frame>
    <description>Renal function evaluated by calculated glomerular filtration rate (cGFR), by three different Formulas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function cGFR</measure>
    <time_frame>36 months</time_frame>
    <description>Renal function evaluated by calculated glomerular filtration rate (cGFR), by three different Formulas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Transplantation Diabetes Mellitus</measure>
    <time_frame>6 months</time_frame>
    <description>The cumulative incidence of Post Transplantation Diabetes Mellitus (PTDM) after transplantation as defined below. Cumulative incidence of
≥2 Fasting Plasma Glucose (FPG) ≥7,0 mmol/L ≥ 30 consecutive days apart. Oral hypoglycaemic treatment ≥30 consecutive days. Insulin ≥30 consecutive days. HgbA1c ≥6.5% (according to American Diabetes Association - ADA)Symptoms of Diabetes and Random Plasma Glucose (RPG) ≥ 11.1 mmol/L.
2-hour Plasma Glucose (2-hPG) ≥ 11.1 mmol/L during an oral glucose tolerance test (OGTT). Baseline OGTT will be performed pre-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Transplantation Diabetes Mellitus</measure>
    <time_frame>12 months</time_frame>
    <description>The cumulative incidence of Post Transplantation Diabetes Mellitus (PTDM) after transplantation as defined below. Cumulative incidence of
≥2 Fasting Plasma Glucose (FPG) ≥7,0 mmol/L ≥ 30 consecutive days apart. Oral hypoglycaemic treatment ≥30 consecutive days. Insulin ≥30 consecutive days. HgbA1c ≥6.5% (according to American Diabetes Association - ADA) Symptoms of Diabetes and Random Plasma Glucose (RPG) ≥ 11.1 mmol/L. 2-hour Plasma Glucose (2-hPG) ≥ 11.1 mmol/L during an oral glucose tolerance test (OGTT). Baseline OGTT will be performed pre-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Transplantation Diabetes Mellitus</measure>
    <time_frame>24 months</time_frame>
    <description>The cumulative incidence of Post Transplantation Diabetes Mellitus (PTDM) after transplantation as defined below. Cumulative incidence of
≥2 Fasting Plasma Glucose (FPG) ≥7,0 mmol/L ≥ 30 consecutive days apart. Oral hypoglycaemic treatment ≥30 consecutive days. Insulin ≥30 consecutive days. HgbA1c ≥6.5% (according to American Diabetes Association - ADA) Symptoms of Diabetes and Random Plasma Glucose (RPG) ≥ 11.1 mmol/L. 2-hour Plasma Glucose (2-hPG) ≥ 11.1 mmol/L during an oral glucose tolerance test (OGTT). Baseline OGTT will be performed pre-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Transplantation Diabetes Mellitus</measure>
    <time_frame>36 months</time_frame>
    <description>The cumulative incidence of Post Transplantation Diabetes Mellitus (PTDM) after transplantation as defined below -Cumulative incidence of:
≥2 Fasting Plasma Glucose (FPG) ≥7,0 mmol/L ≥ 30 consecutive days apart. Oral hypoglycaemic treatment ≥30 consecutive days. Insulin ≥30 consecutive days. HgbA1c ≥6.5% (according to American Diabetes Association - ADA)Symptoms of Diabetes and Random Plasma Glucose (RPG) ≥ 11.1 mmol/L.
2-hour Plasma Glucose (2-hPG) ≥ 11.1 mmol/L during an oral glucose tolerance test (OGTT). Baseline OGTT will be performed pre-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidiabetic medication</measure>
    <time_frame>6 months</time_frame>
    <description>Use of antidiabetic medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidiabetic medication</measure>
    <time_frame>12 months</time_frame>
    <description>Use of antidiabetic medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidiabetic medication</measure>
    <time_frame>24 months</time_frame>
    <description>Use of antidiabetic medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidiabetic medication</measure>
    <time_frame>36 months</time_frame>
    <description>Use of antidiabetic medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antihypertensive and lipid lowering drugs</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence and number of antihypertensive and lipid lowering drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antihypertensive and lipid lowering drugs</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence and number of antihypertensive and lipid lowering drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antihypertensive and lipid lowering drugs</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence and number of antihypertensive and lipid lowering drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>12 months</time_frame>
    <description>Development and magnitude of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>24 months</time_frame>
    <description>Development and magnitude of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>36 months</time_frame>
    <description>Development and magnitude of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>12 months</time_frame>
    <description>Lipid profile (Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, TSH, T4, HbA1c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>24 months</time_frame>
    <description>Lipid profile (Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, TSH, T4, HbA1c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>36 months</time_frame>
    <description>Lipid profile (Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, TSH, T4, HbA1c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytomegalovirus</measure>
    <time_frame>0-36 months</time_frame>
    <description>Incidence of Cytomegalovirus (CMV) that required treatment (CMV-infection and CMV syndrome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malignancy stratified by post-transplant lymphoproliferative disorder (PTLD) and all other cancers.</measure>
    <time_frame>36 months</time_frame>
    <description>Cumulative incidence of malignancy stratified by post-transplant lymphoproliferative disorder (PTLD) and all other cancers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>0-36 months</time_frame>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life, assessed by EQ5D and St Georges Respiratory Questionnaire (SGRQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of life, assessed by EQ5D and St Georges Respiratory Questionnaire (SGRQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>36 months</time_frame>
    <description>Quality of life, assessed by EQ5D and St Georges Respiratory Questionnaire (SGRQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>week 4</time_frame>
    <description>Define the pharmacokinetics of Tacrolimus in non-CF patients (n=12) and all included CF patients (n=15-20) undergoing primary lung transplantation (LTx) treated with an Advagraf® based-immunosuppression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>6 months</time_frame>
    <description>Define the pharmacokinetics of Tacrolimus in non-CF patients (n=12) and all included CF patients (n=15-20) undergoing primary lung transplantation (LTx) treated with an Advagraf® based-immunosuppression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological equipotency of tacrolimus and cyclosporine A</measure>
    <time_frame>0-36 months</time_frame>
    <description>Immunological equipotency of tacrolimus once daily (OD) and cyclosporine A twice daily (BiD) in vivo and in vitro, according to separate protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of treatment failures</measure>
    <time_frame>0-36 months</time_frame>
    <description>Occurrence of treatment failures up to or at 36 months; defined as a composite endpoint of graft loss, death, loss to follow up or discontinuation due to lack of efficacy or toxicity (at least one condition must be present).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery of right heart function</measure>
    <time_frame>0-36 months</time_frame>
    <description>Recovery of right heart function irrespective of diagnosis in patients with pulmonary arterial hypertension (PAH, categories 1-5 according to WHO 1-5).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Lung Transplantation</condition>
  <condition>Allografts</condition>
  <arm_group>
    <arm_group_label>Arm A:Cyclosporine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A: Cyclosporine A, Mycophenolate mofetil (MMF) and corticosteroids according to local practice and approved label.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B:Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B: Tacrolimus (Advagraf), Mycophenolate mofetil (MMF) and corticosteroids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Cyclosporin A (Sandimmun Neoral® or similar):
Cyclosporin A given orally pretransplant in the dose of 2-3 mg/kg.
Continued postop day 1 in the dose of 3mg/kgx2, according to local practice and blood concentration: 0-3 months 250-300; 3-6 months 200-250; 6-12 months 150-200; &gt;12 months 100-150 ng/ml. Cyclosporine A will be administered twice daily.</description>
    <arm_group_label>Arm A:Cyclosporine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil (MMF)</intervention_name>
    <description>MMF target dose: 2000 mg/day (1gx2):
o Controlled by a single Area Under the Curve (AUC) measurement day 90 with a target AUC between 40 and 60 mg.h/L and corrected accordingly.</description>
    <arm_group_label>Arm A:Cyclosporine</arm_group_label>
    <arm_group_label>Arm B:Tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabbit Anti thymocyte globulin</intervention_name>
    <description>Induction therapy: Thymoglobulin® (Rabbit Anti thymocyte globulin)(1.5 mg/kg given immediately postoperatively).</description>
    <arm_group_label>Arm A:Cyclosporine</arm_group_label>
    <arm_group_label>Arm B:Tacrolimus</arm_group_label>
    <other_name>Thymoglobulin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <description>Corticosteroids:
Day 0 (day of lung transplantation); 500+500mg methylprednisolone iv. before reperfusion, i.e. restoration of blood flow into the transplanted allograft.
From day 1: Initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg 3-6 months; less than 0,1 mg/kg &gt; 6 months.</description>
    <arm_group_label>Arm A:Cyclosporine</arm_group_label>
    <arm_group_label>Arm B:Tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus should be given orally pretransplant in the dose of 0.1 mg/kg.
Continued postop day 1 according to local practice and blood concentration: 0-3 months 10-14, 3-6 months 8-12, 6-12 months 8-10, &gt;12 months 6-8 ng/ml. Tacrolimus will be administered once daily.</description>
    <arm_group_label>Arm B:Tacrolimus</arm_group_label>
    <other_name>Advagraf®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Male or female lung recipients 18-70 years of age undergoing primary double (including
             size reduction) lung transplantation.

          2. Patient willing and capable of giving written informed consent for study participation
             and anticipated to be able to participate in the study for 36 months.

        Exclusion Criteria

          1. Recipients of multiorgan transplant, and or previously transplanted with any organ,
             including previous lung transplantation.

          2. Patients with hypersensitivity to, or other reasons to not be able to take the
             immunosuppressive drugs used in the study.

          3. Donor lung cold ischemic time &gt; 12 hours.

          4. Patients who previously have been treated with anti-thymocyte globulin preparations
             (e.g. ATG-Fresenius®, Thymoglobulin®).

          5. Patients who are recipients of ABO-incompatible transplants.

          6. Patients with platelet count &lt; 50,000/mm3 at the evaluation before transplantation.

          7. Patients who are unlikely to comply with the study requirements.

          8. Patients, and/or those receiving organs from donors, who are positive for HIV,
             Hepatitis B surface antigen or Hepatitis C virus.

          9. Patients with donor greater than 75 years.

         10. Patient who have received an unlicensed drug or therapy within one month prior to
             study entry or if such therapy is to be instituted post-transplantation.

         11. Patient unable to participate in the study for the full 36-month period

         12. Patients with any past (within the past 3-5 years) or present malignancy (other than
             excised basal cell carcinoma).

         13. Females capable of becoming pregnant must have a negative pregnancy test prior to
             randomization.

        Females are recommended to practice a medically approved method of birth control for the
        duration of the study and a period of 8 weeks following discontinuation of study
        medication, even where there has been a history of infertility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Göran Dellgren, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sahlgrenska Univ Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Göran Dellgren, MD, PhD</last_name>
    <phone>+46 70 4203680</phone>
    <email>goran.dellgren@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerdt Riise, MD, PhD</last_name>
    <phone>+46 70 4246062</phone>
    <email>gerdt.riise@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Kromann Lund, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Raivio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inga Leukfeldt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Univ Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Göran Dellgren, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gerdt Riise, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Svahn, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vastra Gotaland Region</investigator_affiliation>
    <investigator_full_name>Göran Dellgren</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>chronic lung allograft dysfunction</keyword>
  <keyword>cyclosporin</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>Bronchiolitis Obliterans Syndrome</keyword>
  <keyword>Restrictive Allograft Syndrome</keyword>
  <keyword>CLAD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

